- Home
- PSTV
as 11-21-2024 4:00pm EST
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 7.9M | IPO Year: | N/A |
| Target Price: | $14.00 | AVG Volume (30 days): | 111.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.15 - $2.67 | Next Earning Date: | 11-14-2024 |
| Revenue: | $5,725,000 | Revenue Growth: | 52.63% |
| Revenue Growth (this year): | 11.13% | Revenue Growth (next year): | -6.59% |
Stock Insider Trading Activity of PLUS THERAPEUTICS Inc. (PSTV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hawkins Richard J | PSTV | Director | Sep 13 '24 | Buy | $1.50 | 4,000 | $5,996.00 | 15,188 | |
| Hawkins Richard J | PSTV | Director | Sep 12 '24 | Buy | $1.35 | 6,285 | $8,511.78 | 15,188 | |
| Petersen Greg | PSTV | Director | Sep 11 '24 | Buy | $1.35 | 12,500 | $16,875.00 | 48,921 | |
| Clowes Howard | PSTV | Director | Sep 11 '24 | Buy | $1.34 | 5,000 | $6,681.00 | 26,497 | |
| HEDRICK MARC H | PSTV | Chief Executive Officer | Sep 10 '24 | Buy | $1.23 | 8,000 | $9,839.20 | 20,425 | |
| Sims Andrew John Hugh MacIntyre | PSTV | Chief Financial Officer | Sep 10 '24 | Buy | $1.27 | 4,098 | $5,204.46 | 9,815 |
Latest PLUS THERAPEUTICS Inc. News
PSTV Breaking Stock News: Dive into PSTV Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 hours ago
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
Argus Research
16 hours ago
Daily – Vickers Top Insider Picks for 11/21/2024
Argus Research
2 days ago
Daily – Vickers Top Insider Picks for 11/20/2024
Argus Research
3 days ago
Daily – Vickers Top Insider Picks for 11/19/2024
Argus Research
4 days ago
Daily – Vickers Top Insider Picks for 11/18/2024
Simply Wall St.
5 days ago
Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Argus Research
7 days ago
Daily – Vickers Top Insider Picks for 11/15/2024
GuruFocus.com
7 days ago
Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
Compare PSTV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PSTV PLUS THERAPEUTICS Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.